8:48 AM
Apr 12, 2018
 |  BC Extra  |  Company News

Orchard gains GSK's rare disease gene therapy portfolio

Editor's Note: This article was updated on Apr 12, 2018 at 4:38 PM PDT

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.).

GSK will be eligible to receive undisclosed commercial milestones and royalties. The pharma will hold a 19.9% stake in Orchard and will receive a seat on its board.

In addition to Strimvelis, an ex vivo gene therapy to treat a form of severe combined immunodeficiency (SCID), Orchard will gain two programs in registrational trials, OTL-200 (GSK2696274) to treat metachromatic leukodystrophy (MLD) and OTL-103 (GSK2696275) to treat Wiskott-Aldrich syndrome, as well as an undisclosed clinical program to treat beta-thalassemia. It also will acquire options to exclusively license from Fondazione Telethon and Ospedale...

Read the full 550 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >